Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	US$0.000000	-	1

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 21:33:53 17/07/2026 HKT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	-

14/12/23	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	CI
11/12/23	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	CI

Market Cap	1.17M 1.02M 949K 873K 1.64M 112M 1.68M 11.25M 4.4M 55.27M 4.38M 4.28M 191M	P/E 2021	-2.63x	P/E 2022	-1.23x
Enterprise Value	4.36M 3.81M 3.55M 3.27M 6.13M 417M 6.27M 42.09M 16.45M 207M 16.39M 16.03M 713M	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

14/12/23	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	CI
11/12/23	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	CI
11/12/23	Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	CI
21/11/23	Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	CI
21/11/23	Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	CI
21/11/23	Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	CI
10/11/23	Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/10/23	TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	MT
18/10/23	Top Midday Decliners	MT
17/10/23	Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	MT
17/10/23	Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	CI
10/10/23	Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	MT
14/08/23	Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

18/10/23	TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	MT
27/07/23	Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	MT
16/11/22	Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5	MT
09/09/22	Morgan Stanley Adjusts Price Target on Evelo Biosciences to $4 From $5, Keeps Equalweight Rating	MT
09/09/22	Morgan Stanley Cuts Price Target on Evelo Biosciences to $4 From $5, Maintains Equalweight Rating	MT

Evelo Biosciences, Inc. Stock

Stocks

EVLO

US2997342025

Biotechnology & Medical Research

Valuation: Evelo Biosciences, Inc.

Chart: Evelo Biosciences, Inc.

Latest news : Evelo Biosciences, Inc.

Analysts' recommendations: Evelo Biosciences, Inc.

Press Releases: Evelo Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Evelo Biosciences, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

17/10/23	Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	AQ
14/08/23	Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights	AQ
12/07/23	Evelo Biosciences Closes $25.5 Million Private Placement	AQ
10/07/23	Evelo Biosciences Announces $25.5 Million Private Placement	AQ
29/06/23	Evelo Biosciences Announces Reverse Stock Split Effective	AQ

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		13.93
5 years	0		254.8
10 years	0		398.57

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/11/23	Duncan McHale	Fiscal year	Chief Technology Officer	16,103	0.0855%
7/11/23	Ann Thorell	Fiscal year	Chief Financial Officer	14,811	0.0786%
7/11/23	Mark Bodmer	Fiscal year	Chief Technology Officer	16,413	0.0871%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVELO BIOSCIENCES, INC.	-99.00%	0.00%	-	-	18
ARGENX SE	+0.47%	+2.03%	+51.54%	+70.84%	55.01B
WUXI APPTEC CO., LTD.	+2.83%	+0.04%	+38.07%	+82.59%	54.24B
BIONTECH SE	+0.54%	+0.67%	-17.59%	-13.47%	23.38B
INSMED INCORPORATED	-0.97%	-5.06%	+1.35%	+383.00%	22.57B
WUXI BIOLOGICS (CAYMAN) INC.	+2.07%	+1.44%	+23.06%	-9.05%	20.19B
GENMAB A/S	-2.15%	+0.78%	+24.67%	-31.03%	17.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.14%	-2.72%	+30.26%	+536.72%	15.5B
PHARMAESSENTIA CORPORATION	-3.14%	-8.09%	+160.68%	+292.18%	14.2B
EXELIXIS, INC.	-2.09%	-1.41%	+24.65%	+178.74%	14.2B
Average	-10.36%	-0.50%	+37.41%	+165.61%	23.72B
Weighted average by Cap.	+0.28%	-0.20%	+35.95%	+130.62%

	2021	2022
Net sales	-	-
Net income	-122M -107M -99.42M -91.42M -172M -11.68B -176M -1.18B -460M -5.79B -459M -449M -19.96B	-115M -99.88M -93.2M -85.69M -161M -10.95B -165M -1.1B -432M -5.43B -430M -421M -18.71B
Net Debt	-12.15M -10.59M -9.89M -9.09M -17.05M -1.16B -17.46M -117M -45.77M -576M -45.61M -44.61M -1.98B	3.2M 2.79M 2.6M 2.39M 4.49M 306M 4.6M 30.84M 12.05M 152M 12.01M 11.74M 522M